1. Elevated INR in a COVID‐19 patient after concomitant administration of favipiravir and warfarin: A case report.
- Author
-
Sekimoto, Masao, Imai, Toru, Hidaka, Shinji, Chiba, Nobutaka, Sakurai, Atsushi, Hata, Mitsumasa, and Kikuchi, Norikazu
- Subjects
- *
COVID-19 , *WARFARIN , *ANTIVIRAL agents , *VENOUS thrombosis , *PATIENT monitoring , *DRUG interactions , *INTERNATIONAL normalized ratio , *DRUG side effects - Abstract
What is known and objective: Favipiravir is a promising treatment candidate for managing coronavirus disease 2019 (COVID‐19). Warfarin has many drug interactions, but no interactions with favipiravir have been reported. Case summary: Our patient was taking warfarin for deep vein thrombosis. The international normalized ratio (INR) was stable (1.65 to 2.0); however, it increased to 4.63 after administering favipiravir. The patient had no other factors justifying this change. What is new and conclusion: Favipiravir and warfarin might have previously unidentified drug interactions that elevated the INR. Therefore, INR must be closely monitored when they are concomitantly administered in COVID‐19 patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF